Cargando…
Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report
Pancreatic carcinoma is the leading cause of death among digestive malignancies in China. In particular, there is no breakthrough in prolonging the survival of pancreatic cancer patients with chemical and targeted therapies. Tumor immunotherapy brings opportunities and progress for the treatment of...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894891/ https://www.ncbi.nlm.nih.gov/pubmed/36744247 http://dx.doi.org/10.3389/fphar.2023.1121122 |
_version_ | 1784881830564986880 |
---|---|
author | Ni, Chen-Xu Zhao, Yu Qian, Hong Fu, Hui Yan, Yu-Ying Qiu, Yu-Shuang Zhou, Can-Can Huang, Fang Shen, Fu-Ming Li, Dong-Jie Xu, Qing |
author_facet | Ni, Chen-Xu Zhao, Yu Qian, Hong Fu, Hui Yan, Yu-Ying Qiu, Yu-Shuang Zhou, Can-Can Huang, Fang Shen, Fu-Ming Li, Dong-Jie Xu, Qing |
author_sort | Ni, Chen-Xu |
collection | PubMed |
description | Pancreatic carcinoma is the leading cause of death among digestive malignancies in China. In particular, there is no breakthrough in prolonging the survival of pancreatic cancer patients with chemical and targeted therapies. Tumor immunotherapy brings opportunities and progress for the treatment of pancreatic cancer. Sintilimab is an innovative PD-1 inhibitor which was reported certain clinical benefits in multi-line treatments of advanced pancreatic cancer with gemcitabine. The combination therapy of PD-1 with gemcitabine plus high-intensity focused ultrasound (HIFU) in pancreatic cancer has not been reported. Here we report a case of a Chinese old patient diagnosed with metastatic pancreatic cancer. Two months after sintilimab treatment, the patient occurred severe immune colitis. The patient was diagnosed with immune ureteritis after 8 months of treatment. The immue-related adverse events (irAEs) refined after timely recognition and correct intervention by the clinician and clinical pharmacist. After first-line treatment of sintilimab plus gemcitabine combined with pancreatic HIFU, the patient achieved a remarkable benefit of 11-month progression-free survival (PFS) and 20-month overall survival (OS). The first-line treatment of sintilimab plus gemcitabine combined with HIFU demonstrates a potential therapeutic effect on metastatic pancreatic carcinoma with tolerable adverse reactions. |
format | Online Article Text |
id | pubmed-9894891 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98948912023-02-04 Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report Ni, Chen-Xu Zhao, Yu Qian, Hong Fu, Hui Yan, Yu-Ying Qiu, Yu-Shuang Zhou, Can-Can Huang, Fang Shen, Fu-Ming Li, Dong-Jie Xu, Qing Front Pharmacol Pharmacology Pancreatic carcinoma is the leading cause of death among digestive malignancies in China. In particular, there is no breakthrough in prolonging the survival of pancreatic cancer patients with chemical and targeted therapies. Tumor immunotherapy brings opportunities and progress for the treatment of pancreatic cancer. Sintilimab is an innovative PD-1 inhibitor which was reported certain clinical benefits in multi-line treatments of advanced pancreatic cancer with gemcitabine. The combination therapy of PD-1 with gemcitabine plus high-intensity focused ultrasound (HIFU) in pancreatic cancer has not been reported. Here we report a case of a Chinese old patient diagnosed with metastatic pancreatic cancer. Two months after sintilimab treatment, the patient occurred severe immune colitis. The patient was diagnosed with immune ureteritis after 8 months of treatment. The immue-related adverse events (irAEs) refined after timely recognition and correct intervention by the clinician and clinical pharmacist. After first-line treatment of sintilimab plus gemcitabine combined with pancreatic HIFU, the patient achieved a remarkable benefit of 11-month progression-free survival (PFS) and 20-month overall survival (OS). The first-line treatment of sintilimab plus gemcitabine combined with HIFU demonstrates a potential therapeutic effect on metastatic pancreatic carcinoma with tolerable adverse reactions. Frontiers Media S.A. 2023-01-20 /pmc/articles/PMC9894891/ /pubmed/36744247 http://dx.doi.org/10.3389/fphar.2023.1121122 Text en Copyright © 2023 Ni, Zhao, Qian, Fu, Yan, Qiu, Zhou, Huang, Shen, Li and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Ni, Chen-Xu Zhao, Yu Qian, Hong Fu, Hui Yan, Yu-Ying Qiu, Yu-Shuang Zhou, Can-Can Huang, Fang Shen, Fu-Ming Li, Dong-Jie Xu, Qing Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report |
title | Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report |
title_full | Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report |
title_fullStr | Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report |
title_full_unstemmed | Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report |
title_short | Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report |
title_sort | long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: a case report |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894891/ https://www.ncbi.nlm.nih.gov/pubmed/36744247 http://dx.doi.org/10.3389/fphar.2023.1121122 |
work_keys_str_mv | AT nichenxu longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport AT zhaoyu longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport AT qianhong longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport AT fuhui longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport AT yanyuying longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport AT qiuyushuang longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport AT zhoucancan longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport AT huangfang longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport AT shenfuming longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport AT lidongjie longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport AT xuqing longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport |